Intensified Systemic Therapy and Stereotactic Ablative Radiotherapy Dose for Patients with Unresectable Pancreatic Adenocarcinoma
One-third of patients with pancreatic cancer has unresectable locally advanced disease at the time of diagnosis, and current treatment for these patients consists of a combination of chemotherapy and radiation therapy [1,2]. Historically, gemcitabine has been used as first-line chemotherapy after a pivotal multi-institutional trial showed both substantial clinical benefit and modestly improved survival with gemcitabine compared to 5-fluorouracil [3]. Recently, multiagent chemotherapy regimens have shown significant promise [4-7].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Diego A.S. Toesca, Faisal Ahmed, Mehr Kashyap, J. Richelcyn M. Baclay, Rie von Eyben, Erqi L. Pollom, Albert C. Koong, Daniel T. Chang Tags: Original Article Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Pancreas | Pancreatic Cancer | Radiation Therapy | Radiology